Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
Name:
s41416-018-0082-1.pdf
Size:
472.4Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
Cortes, JTamura, K
DeAngelo, D
de Bono, J
Lorente, D
Minden, M
Uy, G
Kantarjian, H
Chen, L
Gandhi, V
Godin, R
Keating, K
McEachern, K
Vishwanathan, K
Pease, J
Dean, Emma J
Affiliation
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USAIssue Date
2018-05-16
Metadata
Show full item recordAbstract
Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours.Citation
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. 2018, Br J CancerJournal
British Journal of CancerDOI
10.1038/s41416-018-0082-1PubMed ID
29765150Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/s41416-018-0082-1